Loading...
XSWXBION
Market cap2.17bUSD
Dec 20, Last price  
35.40CHF
1D
-0.84%
1Q
-4.45%
Jan 2017
-35.75%
IPO
97.99%
Name

BB Biotech AG

Chart & Performance

D1W1MN
XSWX:BION chart
P/E
—
P/S
—
EPS
—
Div Yield, %
8.05%
Shrs. gr., 5y
-0.20%
Rev. gr., 5y
0.85%
Revenues
-200m
L-43.18%
213,657,000332,660,000318,065,000073,820,00054,293,0001,578,000-1,269,000376,820,000937,893,0001,476,387,000659,227,000-796,446,000693,053,000-465,753,000685,238,000699,233,000-396,220,000-351,227,000-199,567,000
Net income
-207m
L-42.26%
202,752,000317,993,000297,395,000-265,411,00045,353,00036,626,000-146,348,000-65,138,000367,834,000931,834,0001,470,139,000652,816,000-802,065,000687,503,000-471,343,000677,431,000691,174,000-404,808,000-357,812,000-206,607,000
CFO
218m
P
107,318,000-6,141,000-19,804,000201,017,000509,390,000167,838,000-23,411,000169,521,000367,834,000931,834,0001,470,139,000652,816,000-802,065,000687,503,000-471,343,000215,021,000262,449,000-94,787,000-357,812,000218,276,000
Dividend
Mar 25, 20242 CHF/sh
Earnings
Feb 14, 2025

Profile

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
URL
https://www.bbbiotech.ch/
IPO date
Nov 08, 2006
Employees
10
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
(199,567)
-43.18%
(351,227)
-11.36%
(396,220)
-156.66%
Cost of revenue
5,794
5,430
7,352
Unusual Expense (Income)
NOPBT
(205,361)
(356,657)
(403,572)
NOPBT Margin
102.90%
101.55%
101.86%
Operating Taxes
79
61
67
Tax Rate
NOPAT
(205,440)
(356,718)
(403,639)
Net income
(206,607)
-42.26%
(357,812)
-11.61%
(404,808)
-158.57%
Dividends
(156,311)
(212,242)
(199,440)
Dividend yield
6.67%
6.94%
4.67%
Proceeds from repurchase of equity
(27,303)
194
BB yield
0.89%
0.00%
Debt
Debt current
363,000
355,000
Long-term debt
363,000
355,000
Deferred revenue
Other long-term liabilities
(363,000)
(355,000)
Net debt
(5,269,929)
(2,327,297)
(2,933,947)
Cash flow
Cash from operating activities
218,276
(357,812)
(94,787)
CAPEX
Cash from investing activities
588,943
Cash from financing activities
(220,213)
(233,271)
91,768
FCF
2,841,747
231,753
(4,043,548)
Balance
Cash
2,635,215
1,948
2,835
Long term investments
2,634,714
3,051,349
3,641,112
Excess cash
5,279,907
3,070,858
3,663,758
Stockholders' equity
2,359,725
2,722,643
3,292,698
Invested Capital
260,772
326,381
345,637
ROIC
ROCE
EV
Common stock shares outstanding
54,846
55,364
55,364
Price
42.75
-22.55%
55.20
-28.45%
77.15
4.05%
Market cap
2,344,666
-23.28%
3,056,075
-28.45%
4,271,307
3.99%
EV
(2,925,262)
728,778
1,337,360
EBITDA
(205,361)
(356,657)
(403,572)
EV/EBITDA
14.24
Interest
5,802
1,726
986
Interest/NOPBT